# Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

> **NCT05817890** · EARLY_PHASE1 · COMPLETED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fadraciclib

## Key facts

- **NCT ID:** NCT05817890
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-03
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-05-22
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817890, "Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05817890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*